‘Jakavi’ will start to get insurance benefits in this March…the medical industry and patients states “a tremendous welcome”
The myelofibrosis treatment ‘Jakavi (ruxolitinib)’ will finally be in the list of the insurance benefit.
According to the industry concerned on the 4th, Novartis Korea and the National Health Insurance Service recently agreed upon the drug price negotiation for Jakavi. Through the proper procedu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
